{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T20:54:03Z","timestamp":1775854443861,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"9727","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/s0140-6736(10)60491-6","type":"journal-article","created":{"date-parts":[[2010,5,17]],"date-time":"2010-05-17T02:10:34Z","timestamp":1274062234000},"page":"1695-1703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1814,"title":["Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials"],"prefix":"10.1016","volume":"375","author":[{"given":"Kennedy R","family":"Lees","sequence":"first","affiliation":[]},{"given":"Erich","family":"Bluhmki","sequence":"additional","affiliation":[]},{"given":"R\u00fcdiger","family":"von Kummer","sequence":"additional","affiliation":[]},{"given":"Thomas G","family":"Brott","sequence":"additional","affiliation":[]},{"given":"Danilo","family":"Toni","sequence":"additional","affiliation":[]},{"given":"James C","family":"Grotta","sequence":"additional","affiliation":[]},{"given":"Gregory W","family":"Albers","sequence":"additional","affiliation":[]},{"given":"Markku","family":"Kaste","sequence":"additional","affiliation":[]},{"given":"John R","family":"Marler","sequence":"additional","affiliation":[]},{"given":"Scott A","family":"Hamilton","sequence":"additional","affiliation":[]},{"given":"Barbara C","family":"Tilley","sequence":"additional","affiliation":[]},{"given":"Stephen M","family":"Davis","sequence":"additional","affiliation":[]},{"given":"Geoffrey A","family":"Donnan","sequence":"additional","affiliation":[]},{"given":"Werner","family":"Hacke","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(10)60491-6_bib1","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(10)60491-6_bib2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Alteplase compared with placebo within 3 to 4\u00b75 hours for acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(10)60491-6_bib3","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jama.1995.03530130023023","article-title":"Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS)","volume":"274","author":"Hacke","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(10)60491-6_bib4","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(10)60491-6_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/01.STR.31.4.811","article-title":"The rt-PA (alteplase) 0- to 6-hour acute stroke trial, part A (A0267g): results of a double-blind, placebo-controlled, multicenter study","volume":"31","author":"Clark","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/S0140-6736(10)60491-6_bib6","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.282.21.2019","article-title":"Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study\u2014a randomized controlled trial","volume":"282","author":"Clark","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(10)60491-6_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1474-4422(08)70044-9","article-title":"Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial","volume":"7","author":"Davis","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/S0140-6736(10)60491-6_bib8","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(04)15692-4","article-title":"Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials","volume":"363","author":"The","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(10)60491-6_bib9","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(08)61339-2","article-title":"Thrombolysis with alteplase 3\u20134\u00b75 h after acute ischaemic stroke (SITS-ISTR): an observational study","volume":"372","author":"Wahlgren","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(10)60491-6_bib10","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1161\/01.STR.24.7.1000","article-title":"Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke","volume":"24","author":"Haley","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/S0140-6736(10)60491-6_bib11","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/01.STR.20.7.864","article-title":"Measurements of acute cerebral infarction: a clinical examination scale","volume":"20","author":"Brott","year":"1989","journal-title":"Stroke"},{"key":"10.1016\/S0140-6736(10)60491-6_bib12","first-page":"885","article-title":"Multicenter trial of hemodilution in ischemic stroke: background and study protocol","volume":"16","year":"1995","journal-title":"Stroke"},{"key":"10.1016\/S0140-6736(10)60491-6_bib13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","article-title":"Interobserver agreement for the assessment of handicap in stroke patients","volume":"19","author":"Van Swieten","year":"1988","journal-title":"Stroke"},{"key":"10.1016\/S0140-6736(10)60491-6_bib14","first-page":"61","article-title":"Functional evaluation: the Barthel Index","volume":"14","author":"Mahoney","year":"1965","journal-title":"Md State Med J"},{"key":"10.1016\/S0140-6736(10)60491-6_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0140-6736(07)60149-4","article-title":"Thrombolysis with alteplase for acute ischaemic stroke in the Safe implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study","volume":"369","author":"Wahlgren","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(10)60491-6_bib16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa052980","article-title":"NXY-059 for acute ischemic stroke","volume":"354","author":"Lees","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(10)60491-6_bib17","doi-asserted-by":"crossref","first-page":"1347S","DOI":"10.1177\/00928615980320S131","article-title":"Multiple testing: multiple comparisons and multiple endpoints","volume":"32","author":"Chi","year":"1998","journal-title":"Drug Inf J"},{"key":"10.1016\/S0140-6736(10)60491-6_bib18","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1212\/WNL.55.11.1649","article-title":"Early stroke treatment associated with better outcome: the NINDS rt-PA Stroke Study","volume":"55","author":"Marler","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(10)60491-6_bib19","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1161\/STROKEAHA.108.543561","article-title":"Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4\u00b75-hour window: joint outcome table analysis of the ECASS 3 trial","volume":"40","author":"Saver","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/S0140-6736(10)60491-6_bib20","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1161\/STROKEAHA.108.539353","article-title":"After European Cooperative Acute Stroke Study 3: mission accomplished?","volume":"40","author":"Von Kummer","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/S0140-6736(10)60491-6_bib21","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1161\/01.STR.31.12.3034","article-title":"Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke","volume":"31","author":"Lapchak","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/S0140-6736(10)60491-6_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(08)70267-9","article-title":"Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion\u2013diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study","volume":"8","author":"Hacke","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/S0140-6736(10)60491-6_bib23","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1148\/radiol.2513081074","article-title":"Acute stroke triage to intravenous thrombolysis and other therapies with advanced CT or MR imaging: pro MR imaging","volume":"251","author":"K\u00f6hrmann","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/S0140-6736(10)60491-6_bib24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1148\/radiol.2513081073","article-title":"Acute stroke triage to intravenous thrombolysis and other therapies with advanced CT or MR imaging: pro CT","volume":"251","author":"Wintermark","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/S0140-6736(10)60491-6_bib25","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1056\/NEJMoa041175","article-title":"Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke","volume":"351","author":"Alexandrov","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(10)60491-6_bib26","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1161\/STROKEAHA.108.517656","article-title":"The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial","volume":"39","author":"Pancioli","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/S0140-6736(10)60491-6_bib27","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archneur.63.8.1057","article-title":"Argatroban tPA stroke study: study design and results in the first treated cohort","volume":"63","author":"Sugg","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/S0140-6736(10)60491-6_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1747-4949.2008.00151.x","article-title":"Methodology of the Interventional Management of Stroke III Trial","volume":"3","author":"Khatri","year":"2008","journal-title":"Int J Stroke"},{"key":"10.1016\/S0140-6736(10)60491-6_bib29","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1161\/01.STR.0000124458.98123.52","article-title":"Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial","volume":"35","author":"Saver","year":"2004","journal-title":"Stroke"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673610604916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673610604916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T23:58:37Z","timestamp":1758844717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673610604916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":29,"journal-issue":{"issue":"9727","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0140673610604916"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(10)60491-6","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.3790971.3523071","asserted-by":"object"}]},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(10)60491-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(10)60634-4","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}